Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates Significant Additional Improvement for Patients on Pagoclone

LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persistent developmental stuttering will be presented today at the 47th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), sponsored by National Institute for Mental Health (NIMH) and being held in Boca Raton, Florida. In addition, the presentation will include data from the first three months of open label treatment.

"The progress of the ongoing Phase II open-label phase has been extremely encouraging," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "Our investigators are reporting significant benefit for the vast majority of patients continuing in the open label phase and for several patients, these benefits have been life-changing."

"The results from the open-label extension study reveal that pagoclone is a promising medication for the long-term treatment of stuttering," stated Gerald A. Maguire, M.D., associate professor, department of psychiatry, University of California, Irvine School of Medicine. "As a researcher and a person who stutters, I am excited about the results. Although there is no cure for stuttering, this study suggests that pagoclone holds significant promise as a well-tolerated, effective pharmacologic treatment for stuttering and further studies are indicated."

The open label data demonstrated an improvement in nearly all efficacy measures compared to baseline that was at least double the magnitude seen in the initial 8 weeks of double-blind treatment. During the 8-week, double-blind portion of the study, patients who were randomized to placebo experienced a mean reduction in the percentage of syllables stuttered of 5%. After three months i
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/4/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/bqfsp3/transdermal_drug ... PharmaBiotech,s new report "Transdermal Drug Delivery ... their offering. This report ... approach used to deliver drugs through the ... to oral,intravascular, subcutaneous and transmucosal routes. Various ...
(Date:8/4/2015)... 4, 2015 BioElectronics Corporation (OTC Pink: ... Pain Therapy medical devices, announced today that its ... 7-day trial device has been published in the ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic ... an assessment.  Chronic pain is ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, ... focused on the development and commercialization of targeted ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... August 6, 2015 TIME: 12:15PM EDT LINK: ... a live, interactive online event where investors are ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... 5 Transgenomic, Inc. (OTC,Bulletin Board: TBIO), a ... has entered into agreements with two major Pharmaceutical,companies ... $500,000 in the,first half of 2008., "These ... commitments reflect increasing customer validation of our unique,mutation ...
... Inc.,(Amex: PLC ), a company focused on innovative ... for the three,and twelve month periods ended December 31, ... compared with,$1,747,000 in the fourth quarter of 2006. The ... or $0.03 per diluted share, compared to net,income of ...
Cached Medicine Technology:Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies 2PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6
(Date:8/4/2015)... St. Louis, Missouri (PRWEB) , ... August 04, ... ... Automated Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership ... 30-year track record of sales success at technology companies and expanding global markets ...
(Date:8/4/2015)... ... , ... Montclair State University and Atlantic Health System have launched a new ... Jersey, which starting this Fall will help prepare those entering this burgeoning, hybrid field. ... System, one of the largest health care organizations in New Jersey, to design the ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics ... the customer experience inside Naimie’s Beauty Center in LA. Now MENAJI is part of ... look better. , Naimie’s Beauty Center has been a favorite of makeup artists and ...
(Date:8/4/2015)... (PRWEB) , ... August 04, ... ... its HealthCenter personal health record (PHR) product has achieved Office of the ... Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... healthcare finance, announced the closing of a $118 million FHA-insured loan modification refinancing ... located in Smithfield and Clayton, North Carolina. JHSC is a joint venture ...
Breaking Medicine News(10 mins):Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3
... Additional beneficial effects on cardiometabolic risk factors beyond those ... drug rimonabant may not be due to the drug ... Drug and Therapeutics Bulletin (DTB). ,Advertisements ... Sanofi-Aventis) claim that an estimated 50% of the effects ...
... Cryo-Save Group NV together with the University of Cologne ... collect adult mesenchymal stem cells ("MSCs") from the ... allows the collection and cryopreservation of very high quantities ... ,Mesenchymal stem cells (MSCs) are of great therapeutic ...
... current rehab spell will bring a stop to her suicidal ... ,As the Mean Girls star checked into the Promises ... arrested for DUI, her supposed friends got ready to reveal ... America's Star magazine that Lohan attempted to take her own ...
... to enter rehab in order to get rid of his addiction ... was recently snapped in a sleazy romp with two hookers, admitted ... ,"Im a bad boy. I go out and get drunk, ... with the wrong women. Ive been sowing my oats for years, ...
... unabated across the Atlantic. But the man who set off ... Denver that specializes in the disease. The man himself ... Atlanta. He is not coughing, has no fever and does ... said. ,Still, staff at the National Jewish Medical ...
... double current funding levels for the President's Emergency Plan ... years after the program's original mandate expires next year, ... $15 billion over five years for HIV/AIDS and tuberculosis ... the Global Fund To Fight AIDS, Tuberculosis and Malaria. ...
Cached Medicine News:Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Significant Scientific Breakthrough in Stem Cell Banking 2Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2
... the latest technology and innovative software with ... transmission and auto detection of progressive lenses. ... network with the VELO 8500 Motorized Refractor ... the future. , ,*VELOtm Aculens 186UV can ...
...
...
...
Medicine Products: